This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Drug Therapy  • Adverse Effects  • Immunologic Disorders  • Alert me on articles by topic

Markus Krumbholz, MD; Hannah Pellkofer, MD; Ralf Gold, MD; Lisa Ann Hoffmann, MD; Reinhard Hohlfeld, MD; Tania Kümpfel, MD

	Since this article does not have an abstract, we have provided the first 115 words of the full text and any section headings.

In reply

The case reported by Leussink and colleagues shows striking parallels with our previously described case of a delayed allergic reaction to natalizumab. We fully agree that we must anticipate additional cases of such delayed, type III systemic reactions to natalizumab in the future. The twopublished cases should help to raise awareness of this type of complication.

AUTHOR INFORMATION

Correspondence: Dr Krumbholz, Institute for Clinical Neuroimmunology, Ludwig Maximilian University, Marchioninistraße 15, 81377 Munich, Germany (krumbholz@neuro.mpg.de).

Financial Disclosure: Drs Gold and Hohlfeld have received grant support and consultancy fees from Schering, Teva, Serono, and Biogen Idec.

Arch Neurol. 2008;65(6):852.

RELATED LETTERS

Delayed Allergic Reaction to Natalizumab Associated With Early Formation of Neutralizing Antibodies
Markus Krumbholz, Hannah Pellkofer, Ralf Gold, Lisa Ann Hoffmann, Reinhard Hohlfeld, and Tania Kümpfel
Arch Neurol. 2007;64(9):1331-1333.
ABSTRACT | FULL TEXT  

Type III Systemic Allergic Reaction to Natalizumab
Verena I. Leussink, Helmar C. Lehmann, Hans-Peter Hartung, Ralf Gold, and Bernd C. Kieseier
Arch Neurol. 2008;65(6):851-852.
EXTRACT | FULL TEXT